



# SUDARSHAN PHARMA INDUSTRIES LTD

**Head Office :** 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

**E-mail :** compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

**Board Line :** +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/25

Date: 19<sup>th</sup> June, 2025

To,

**The Listing Department  
BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

**Sub: Intimation for Board approval for incorporating a Limited Liability Company in Canada as a wholly-owned Subsidiary of the Company**

**Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have approved to incorporate a wholly-owned subsidiary Company in Canada, which will be a subsidiary of the Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024 are given in Annexure A.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited

Sachin Mehta  
Joint Managing Director



Encl: As above



# SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com), Website : [www.sudarshanpharma.com](http://www.sudarshanpharma.com)

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

## Annexure-A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024 are given below:

Sl. No.	Details to be Provided	Information
1	Name of the target entity, details in brief such as size, etc.	<b>Name:</b> To incorporate a company as a wholly-owned subsidiary company with such name as maybe made available for incorporation.
2	whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	NA
3	industry to which the entity being acquired belongs.	Manufacturing of Chemical & Pharmaceutical products & to trade in General & FMCG goods.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The incorporation of the proposed subsidiary company will allow the Company to establish a place of business in the Canada.
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Approval of the Reserve Bank of India under Foreign Exchange Management Act, 1999 Foreign Exchange Management (Overseas Investment), Rules, Regulations and Directions, 2022 as may be amended from time to time (approval under automatic route).
6	Indicative time period for completion of the incorporation	6 months
7	Nature of Consideration whether Cash consideration or share swap and details of the same	NA
8	Cost of acquisition or the price at which the shares are acquired.	NA





# SUDARSHAN PHARMA INDUSTRIES LTD

**Head Office :** 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

**E-mail :** compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

**Board Line :** +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

9	Percentage of shareholding control acquired and / or number of shares acquired	100%
10	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	NA

For, Sudarshan Pharma Industries Limited

Sachin Mehta  
Joint Managing Director

